While the GRIPHON study and others have confirmed the efficacy and safety of selexipag with single, dual, and initial triple combination therapy for patients with pulmonary arterial hypertension (PAH), multicenters… Click to show full abstract
While the GRIPHON study and others have confirmed the efficacy and safety of selexipag with single, dual, and initial triple combination therapy for patients with pulmonary arterial hypertension (PAH), multicenters studies concerning diverse triple oral combination therapies based on selexipag are limited.
Keywords:
oral combination;
combination;
triple oral;
arterial hypertension;
combination therapies;
pulmonary arterial
Journal Title: Clinical Cardiology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cardiology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!